Kodiak Sciences Inc. (KOD) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($181.3M bought vs $2.7M sold). Latest close $97.81 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 5, 2026 · Congress to Nov 16, 2026.
Baker Bros. Advisors · RTW Investments · Polen Capital Management — 3 tracked funds hold KOD. See all holders.
Insiders bought on the open market (86 purchases, $181.3M) vs 8 sales ($2.7M). Latest buy: Nov 5, 2026. Insider trading
Aktis Oncology, Inc. (AKTS) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · Taysha Gene Therapies, Inc. (TSHA) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Baker Bros. Advisors | 3.89% | 19,919,186 | HELD Q3 filed Nov 16 |
| RTW Investments | 0.49% | 1,487,934 | HELD Q3 filed Nov 16 |
| Polen Capital Management | 0.01% | 35,469 | TRIMMED (-14.2%) Q3 filed Nov 13 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +159.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 203 of 8,857 filers |
| Long-only filers among them | 200 |
| Change vs 2026 Q1 | +18 net · 199 entered · 181 exited |
| Shares reported, all filers | 60,475,613 |
| Reported value, all filers | $2.2B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Net income · FY2025 | $-230.0M |
| Total assets · FY2025 | $351.5M |
| Shares outstanding | 62,849,457 |
| Market cap (at latest close) | $6.1B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 6, 2026.
| Shares short · Oct 15, 2026 | 8,500,479 |
| Share of shares outstanding | 13.53% |
| Days to cover | 4.24 |
Shares short at recent settlements — Jul 31, 2026: 10.2M · Aug 14, 2026: 10.3M · Aug 31, 2026: 10.8M · Sep 15, 2026: 10.7M · Sep 30, 2026: 9.4M · Oct 15, 2026: 8.5M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 6, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 3 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 6, 2026.
1 insider bought on the open market in the last 90 days (86 purchases, $181.3M), against 8 sales by 1 insider ($2.7M). Latest buy: Nov 5, 2026.
$1M+ open-market buySource: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| BAKER BROS. ADVISORS LP · 4,703 shares on Nov 5, 2026 · filed Nov 6, 2026 | $98.51 | -9.6% (close Nov 9, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Nov 9, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | BAKER BROS. ADVISORS LP | Buy | 4,703 | $98.51 | $463.3K | SEC filing | |
| Nov 5, 2026 | BAKER BROS. ADVISORS LP | Buy | 81,729 | $98.51 | $8.1M | SEC filing | |
| Nov 4, 2026 | BAKER BROS. ADVISORS LP | Buy | 8,742 | $98.51 | $861.2K | SEC filing | |
| Nov 4, 2026 | BAKER BROS. ADVISORS LP | Buy | 151,916 | $98.51 | $15.0M | SEC filing | |
| Oct 21, 2026 | BORGESON JOHN A. | Chief Financial Officer | Sell | 8,514 | $87.67 | $746.4K | SEC filing |
| Oct 21, 2026 | BORGESON JOHN A. | Chief Financial Officer | Sell | 1,677 | $89.20 | $149.6K | SEC filing |
| Oct 21, 2026 | BORGESON JOHN A. | Chief Financial Officer | Sell | 7,623 | $89.74 | $684.1K | SEC filing |
| Oct 21, 2026 | BORGESON JOHN A. | Chief Financial Officer | Sell | 5,101 | $90.98 | $464.1K | SEC filing |
| Oct 21, 2026 | BORGESON JOHN A. | Chief Financial Officer | Sell | 2,985 | $91.76 | $273.9K | SEC filing |
| Oct 21, 2026 | BORGESON JOHN A. | Chief Financial Officer | Sell | 2,000 | $92.66 | $185.3K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | JOHN BORGESON | Officer | 30,000 | $1.0M | Jun 4, 2026 | SEC filing |
| Apr 2, 2026 | JOHN BORGESON | Officer | 30,000 | $1.3M | Apr 2, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Sep 30, 2026 | SCHEDULE 13D/A | -1.7% (close Oct 1, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Oct 1, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Baker Bros. Advisors LP | SC 13D/A | 22,049,297 | 35.0% | Sep 28, 2026 | SEC filing |
| Aug 14, 2026 | T. Rowe Price Associates, Inc. | SC 13G | 3,248,611 | 5.2% | Jun 30, 2026 | SEC filing |
| May 15, 2026 | Sirenia Capital Management LP | SC 13G | 3,495,000 | 5.7% | Mar 31, 2026 | SEC filing |
| Apr 27, 2026 | BlackRock, Inc. | SC 13G | 3,273,386 | 5.3% | Mar 31, 2026 | SEC filing |
| Apr 2, 2026 | POINT72 ASSET MANAGEMENT, L.P. | SC 13G | 609,806 | 1.0% | Mar 26, 2026 | SEC filing |
| Feb 17, 2026 | D. VICTOR PERLROTH, M.D. | SC 13G/A | 6,504,427 | 9.9% | Dec 31, 2025 | SEC filing |
| Feb 17, 2026 | Point72 Asset Management, L.P. | SC 13G/A | 2,166,929 | 3.5% | Dec 31, 2025 | SEC filing |
| Dec 19, 2025 | Baker Bros. Advisors LP | SC 13D/A | 20,067,542 | 32.8% | Dec 18, 2025 | SEC filing |
| Aug 19, 2025 | Point72 Asset Management, L.P. | SC 13G | 2,908,836 | 5.5% | Aug 15, 2025 | SEC filing |
| Apr 29, 2025 | BlackRock, Inc. | SC 13G/A | 2,301,991 | 4.4% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Insiders
· Large Insider Buys — Last 90 days: a single buy trade of $1M or more
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· 52-Week High — Recently printed a new 52-week high
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Large Insider Buys — Buy value: $181.3M · Buy txns: 86 · Insiders buying: 1 · Latest buy: Nov 5, 2026
· Insider Net Buying — Buy txns: 86 · Sell txns: 8 · Buy value: $181.3M · Latest buy: Nov 5, 2026
· Distress Risk (Altman Z″) — Z″-Score: -14.93 · Working capital / assets: 0.48 · Retained earnings / assets: -4.43 · EBIT / assets: -0.67 · Equity / liabilities: 0.81
· Excess Accruals (Sloan) — Accruals ratio: -26.6% · Net income: $-230.0M · Operating cash flow: $-136.0M · Investing cash flow: $-506.0K
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold KOD — ranked by lift, the co-holding pattern described in Methodology: Aktis Oncology, Inc. (AKTS) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · Taysha Gene Therapies, Inc. (TSHA) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN).
5 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 28, 2026 | 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 13, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Aktis Oncology, Inc. (AKTS) · Track Record: how the signals scored · Practice timing on KOD
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.